BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
July 23 2024 - 7:30AM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company focused on
genetic diseases, announced that Thomas Trimarchi, Ph.D., has been
appointed President and Chief Operating Officer (COO) of the
company. Dr. Trimarchi will assume his new responsibilities
effective immediately and will continue to report directly to CEO
and founder, Neil Kumar, Ph.D.
In this newly created position, Dr. Trimarchi will be
responsible for driving operational excellence, strategic planning,
and overall business success at BridgeBio. He will lead
cross-functional activities to develop a centralized operation
across the late-stage pipeline prioritizing efficiency, rigor, and
scale.
“I’m thrilled to partner with Tom in his new role, and excited
to continue to learn from him. Tom thinks independently, puts
patients first, understands that every minute counts for the
patients we serve, and lets science and data dictate his
decision-making,” said Dr. Kumar. “He has been a tremendous part of
building BridgeBio into what it is today, and I look forward to
seeing his continued growth as a leader enable us to have
ever-better impact on patients.”
Dr. Trimarchi has served in roles of increasing responsibility
since joining BridgeBio in 2018, most recently as the Chief Product
Officer. He is also a board member of ML Bio Solutions, a BridgeBio
affiliate focused on developing BBP-418 for limb-girdle muscular
dystrophy type 2I/R9 (LGMD2I/R9), since November 2021. Prior to
joining the company, Dr. Trimarchi worked at Regeneron
Pharmaceuticals, Inc., and Goldman Sachs after receiving his Ph.D.
in Molecular Oncology and Immunology from New York University.
“I am inspired every day by the work the teams are doing at
BridgeBio to serve patients and families impacted by genetic
diseases. The BridgeBio team is deeply passionate about the
meaningful work they are doing to create and deliver transformative
medicines with a patients-first mindset,” said Dr. Trimarchi. “I
feel lucky to be stewarding our mission alongside Neil and Brian.
We are just getting started on delivering life-changing treatments
for as many patients as possible.”
About BridgeBio Pharma, Inc.BridgeBio Pharma,
Inc. is a commercial-stage biopharmaceutical company founded to
discover, create, test, and deliver transformative medicines to
treat patients who suffer from genetic diseases. BridgeBio’s
pipeline of development programs ranges from early science to
advanced clinical trials. BridgeBio was founded in 2015 and its
team of experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help patients
as quickly as possible. For more information
visit bridgebio.com and follow us
on LinkedIn and Twitter.
BridgeBio Contact:Vikram
Balicontact@bridgebio.com(650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Aug 2023 to Aug 2024